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Background: MYC family members are among the most frequently deregulated oncogenes in human cancers, yet
direct therapeutic targeting of MYC in cancer has been challenging thus far. Synthetic lethality provides an opportunity
for therapeutic intervention of MYC-driven cancers.
Methods: A pooled kinase shRNA library screen was performed and next-generation deep sequencing efforts identified
that PRKDC was synthetically lethal in cells overexpressing MYC. Genes and proteins of interest were knocked down or
inhibited using RNAi technology and small molecule inhibitors, respectively. Quantitative RT-PCR using TaqMan probes
examined mRNA expression levels and cell viability was assessed using CellTiter-Glo (Promega). Western blotting was
performed to monitor different protein levels in the presence or absence of RNAi or compound treatment. Statistical
significance of differences among data sets were determined using unpaired t test (Mann–Whitney test) or ANOVA.
Results: Inhibition of PRKDC using RNAi (RNA interference) or small molecular inhibitors preferentially killed
MYC-overexpressing human lung fibroblasts. Moreover, inducible PRKDC knockdown decreased cell viability selectively
in high MYC-expressing human small cell lung cancer cell lines. At the molecular level, we found that inhibition of
PRKDC downregulated MYC mRNA and protein expression in multiple cancer cell lines. In addition, we confirmed that
overexpression of MYC family proteins induced DNA double-strand breaks; our results also revealed that PRKDC
inhibition in these cells led to an increase in DNA damage levels.
Conclusions: Our data suggest that the synthetic lethality between PRKDC and MYC may in part be due to PRKDC
dependent modulation of MYC expression, as well as MYC-induced DNA damage where PRKDC plays a key role in
DNA damage repair.
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Targeted therapies inhibiting druggable gain-of-function
oncogenes such as BCR-ABL, EGFR, HER2, ALK, and
mutant BRAF have shown striking benefits in cancer pa-
tients in the clinic. However, many challenges remain for
targets which lack druggable domains, such as RAS and
MYC, two of the most frequently deregulated human
oncogenes [1-4].* Correspondence: jliu@gnf.org
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unless otherwise stated.MYC family members (c-, L-, and N-) are ubiquitously
expressed in mammals, exhibit similar biological func-
tions, and are under tight regulation throughout develop-
ment and adulthood. MYC is found downstream of a
number of growth factor receptors, acting as a central hub
directing signals that favor various aspects of cell growth,
such as cell proliferation and resistance to apoptosis [5].
Rather than a direct mutation of MYC, overexpression of
this oncoprotein is the major underlying mechanism of
action for its tumor-promoting properties [5].
Due to the lack of a druggable domain, it has been chal-
lenging to develop small molecule inhibitors that target
MYC itself, or disrupt MYC-mediated protein-protein orhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pression in normal cells including regenerative tissues
such as the gastrointestinal tract, skin and bone mar-
row, raises concern for achieving an acceptable thera-
peutic index in MYC-targeted therapies. To this end, a
dominant-negative MYC mutant (OmoMyc) was devel-
oped to inhibit MYC’s interaction with its key binding
partner, MAX [8-10]. The disruption of this heterodi-
merization resulted in inhibition of MYC-dependent
target gene expression [11-13]. OmoMyc-mediated
MYC inhibition led to a dramatic decrease in tumor-
burden in a murine Kras lung cancer model, with only
mild side effects [14,15], suggesting differential MYC
dependency between tumor and normal tissues.
For non-druggable targets like MYC, synthetic lethality
offers a unique opportunity for therapeutic intervention.
The principle of synthetic lethality is that mutation of ei-
ther gene ‘A’ or ‘B’ alone is non-detrimental to the cell,
while mutation of both genes leads to cell death [16,17].
For example, the Parp1 inhibitor is synthetic lethal to
cells harboring BRCA1/2 mutations [18-20]. In phase II
clinical trials, the PARP1 inhibitor, Olaparib, showed a
41% response rate as a single agent in breast and ovarian
cancer patients with BRCA1/BRCA2 mutations [21,22].
Towards identifying novel synthetic lethality targets,
RNA interference (RNAi) technology has made it feas-
ible to investigate a large cohort of genes for loss-of-
function effects [23].
In our quest to reveal novel synthetic lethal genes in
the context of MYC-deregulated cancers, we conducted
a pooled shRNA screen using isogenic cell lines. We iden-
tified and confirmed PRKDC (Protein Kinase, DNA-
activated, Catalytic polypeptide), a protein kinase with a
major role in non-homologous end joining (NHEJ) DNA
repair [24,25]), as a novel synthetic lethal target in MYC-
overexpressing lung cancer cells. We found that downreg-
ulation of PRKDC expression in MYC-overexpressing
cells led to a significant reduction of MYC-dependent cell
proliferation. Additionally, PRKDC can modulate MYC
mRNA and protein expression levels. Moreover, our data
reconfirmed that overexpression of MYC family proteins
induced DNA double-strand breaks, and we further dem-
onstrated an increase in DNA damage upon PRKDC in-
hibition in cells overexpressing MYC. Altogether, our
results indicate that PRKDC may be critical in MYC-
driven oncogenesis, and support PRKDC as a potential
synthetic lethal target for MYC.
Methods
Antibodies and western blot analyses
The following primary antibodies were used in western
blot: γH2AX (1:2000 dilution, Millipore, cat# 05–636),
GAPDH (1:1000 dilution, Cell signaling, cat# 3683),
gamma-tubulin (1:5000, Thermo Scientific cat#MA1-850),c-MYC (1:1000, Cell signaling, cat# 5605), N-MYC
(1:1000, Cell signaling, cat# 9405), L-MYC (1:1000, R&D
systems, cat# AF4050) and PRKDC (1:200 dilution, Santa
Cruz, cat# sc-9501). For immunoblots, cells were lyzed
with either CelLytic M cell lysis buffer (Sigma) or RIPA
buffer (Sigma cat#89900) and equal amounts of protein
lysates were mixed with XT sample buffer and reducing
agent (Bio-Rad), separated by SDS Criterion precast
gels (Bio-Rad), and transferred to a PVDF membrane
(Bio-Rad). Proteins were detected with primary antibodies
and horseradish peroxidase-conjugated secondary anti-
bodies by using SuperSignal West Dura Extended
Duration Substrate (Thermo Scientific).
Plasmids and chemical inhibitors
shRNAs pLKO.1 lentiviral plasmids used for non-
targeting shRNA control (SHC002) and human PRKDC
knockdown were purchased from Sigma. The shRNA
clones used for targeting PRKDC were TRCN0000197152
(shPRKDC#1), TRNC0000196328 (shPRKDC#2), TRCN
0000195491 (shPRKDC#3), TRCN0000194985 (shPRK
DC#4) and TRCN0000194719 (shPRKDC#5). Non-
targeting control shRNA and three PRKDC shRNAs
(shPRKDC#1, shPRKDC#3 and shPRKDC#5) were cloned
into the inducible pLKO-Tet-On puromycin vector as
previously described [26]. pCDH-CMV-MCS-EF1-Puro
lentivector was purchased from System Bioscience.
pCDH-c-MYC, pCDH-L-MYC1, pCDH-L-MYC2 and
pCDH-N-MYC vectors were generated by cloning protein
coding sequences of human c-MYC, L-MYC isoform1, L-
MYC isoform2 and N-MYC into pCDH-CMV-MCS-EF1-
Puro lentivector. Etoposide, NU-7441, and KU0060648
were obtained from Sigma (cat# E1383), Tocris Cookson
Inc. (cat# 3712), and Axon Medchem BV (cat# Axon
1584), respectively. The proteasome inhibitor, MG132,
was obtained from Sigma (cat#C2211).
Cell culture
All cell lines were cultured in a humidified incubator at
37°C with 5% CO2. The following cell lines were ob-
tained from ATCC: HEK 293 T, WI-38, WI-38 VA 13,
Daudi, EB1, HS604T, HS616T, HuT 102, MC116,
Namalwa, H1963, H196, H209, H526, H524, H82, H69,
Raji, SW1271, and TO175T. DEL, L428, SU-DHL-10,
WSU-DLCL2, Jurkat, DND41 and SR768 were pur-
chased from DSMZ. A4/Fuk was obtained from JCRB
Cell Line Bank. OCI-Ly3 was a kind gift from Dr. Mark
Minden (University Health Network Toronto). The hu-
man lung fibroblast cell lines WI-38 and WI-38 VA13
were routinely cultured in EMEM supplemented with
10% Fetal Bovine Serum (FBS). SCLC cell lines H1963,
H196, SW1271, H209, H526, H524, H82 and H69 were
maintained in RPMI 1640 with 10% FBS. The lymphoma
cell lines EB1, Daudi, Raji, A4/Fukuda, Jurkat, DND41,
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cultured in RPMI 1640 with 10% FBS. MC116 and SU-
DHL-10 cells were maintained in RPMI 1640 with 20%
FBS. OCI-Ly3 cells were cultured in IMDM with 20%
FBS. The SR786 cell line was cultured in RPMI 1640
with 15% FBS. HS604T cells were maintained in DMEM
with 10%FBS and 2 mM Glutamine. HS616T and
TO175T cell lines were cultured in DMEM with 10%
FBS. HEK 293 T cells were maintained in DMEM with
10% FBS. All cell lines were maintained with a cocktail
of penicillin and streptomycin (Gibco).
Lentivirus and infection
Lentivirus packaging and infection was performed ac-
cording to the established protocols from the RNAi
consortium (http://www.broadinstitute.org/rnai/public/
resources/protocols). Briefly, shRNA-encoding plasmids
were transfected into 293 T cells with packaging plas-
mids encoding gag-pol-rev and vesicular stomatitis
virus envelope glycoprotein using Fugene6 (Roche).
Growth media was changed the following day and
lentivirus-containing supernatants were harvested 2–3
days after transfection, filtered and used to infect cells
in the presence of 8 μg/ml polybrene (Sigma).
Generation of stable inducible shRNA-expressing cell lines
To generate tet-inducible stable cell lines, SCLC cell
lines were transduced with lentivirus expressing tet-
inducible shRNA against PRKDC or non-targeting con-
trol in the presence of 8 μg/ml polybrene (Sigma).
Medium was changed the following day and cells were
selected by puromycin and expanded for at least one
week before performing experiments. Induction of
shRNA expression was performed by addition of
100 ng/ml doxycycline (Clontech) to the cell culture
medium.
Cell viability assay
Cell viability assay was performed using CellTiter-Glo
(Promega) according to manufacturer’s instructions.
Briefly, cells were seeded at 3000 cells/well in a 96-well
plate (6 wells/sample) in the presence and absence of
doxycycline. CellTiter-Glo measurements were taken at
several time points to track cell proliferation.
RNA extraction and quantitative RT-PCR (TaqMan)
Total RNA was isolated using the Qiagen RNeasy kit
according to the manufacturer’s instructions. cDNA
was generated from 0.5 μg total RNA using High Cap-
acity cDNA Reverse Transcription kit (ABI). TaqMan
probes include c-MYC (Hs00153408_m1), N-MYC
(Hs00232074_m1), L-MYC1 (Hs00420495_m1), L-MYC2
(Hs01921478_s1) and PRKDC (Hs00179161_m1) (ABI).TaqMan PCR was performed by using the ABI PRISM
7900 HT Sequence Detection System. All experiments
were performed in triplicate and normalized to GAPDH.
Pooled shRNA screening
pGW-LentLox3.7 lentiviral-based human kinome shRNA
library containing 1300 shRNAs (targeting 500 human
kinase genes, 2–3 shRNAs per gene) was designed and
constructed by Genomics Institute of the Novartis Re-
search Foundation (GNF). 1300 lentiviral kinase shRNA
plasmids and non-targeting control shRNA plasmids were
combined at equal concentration in one pool and used to
generate pooled lentivirus. For screening, three WI-38 iso-
genic cell lines (overexpressing L-MYC1, L-MYC2 or
empty vector control) were infected with the pooled lenti-
virus using a MOI of 0.5. Medium was changed the fol-
lowing day and twenty-four hours later, 2×106 cells were
harvested as day 1 sample. 2×106 cells were further cul-
tured for 14 days (day 14 sample). Genomic DNA from
day 1 and day 14 samples was isolated by using a DNeasy
blood & tissue kit (Qiagen). Deep-sequencing template li-
braries were generated by PCR amplification of shRNA
hairpin from genomic DNA. PCR products were purified
by using a QIAquick PCR purification kit (Qiagen). After
purification, PCR products from each sample were quanti-
fied, pooled at equal proportions and analyzed by high-
throughput sequencing (Eureka).
Statistical analysis
All numerical data are shown as mean ± SD or SEM.
Error bars on all graphs represent the standard deviation
or SEM between measurements. Statistical significance
of differences among data sets were determined using
unpaired t test (Mann–Whitney test) or one-way ANOVA
using PRISM 6 (GraphPad, San Diego, CA). P values are in-
dicated with asterisks (****P ≤0.0001; ***P ≤ 0.001; **P ≤ 0.01;
*P ≤ 0.05).
Results
Large scale RNAi screen using L-MYC-overexpressing cells
uncovers PRKDC as a novel candidate for synthetic
lethality
In our pursuit to uncover novel synthetic lethality tar-
gets of the MYC signaling pathway, we conducted a
large scale loss-of-function RNAi screen in L-MYC-
overexpressing lung fibroblasts and their isogenic con-
trols. Here, we used an in-house pooled kinase shRNA
library (1279 shRNA constructs targeting 486 human
kinase genes). We screened the lung fibroblast cell line,
WI-38, stably expressing empty vector, L-MYC isoform
1 (L-MYC1) or L-MYC isoform 2 (L-MYC2) (overex-
pressing an inactive L-MYC transcriptional variant),
with our lentiviral shRNA library. Genomic DNA was
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ation sequencing. The change in relative abundance of each
shRNA among the three WI-38 cell lines was analyzed.
Our primary screening hits include both novel candi-
dates, and previously reported genes functioning as
synthetic lethal partners with MYC, such as CDK2 and
GSK3B; CDK2 and GSK3B served as positive controls
in this screen [27,28] (Figure 1 and Additional file 1:
Table S1). We identified a small cohort of potential
MYC synthetic lethal partners as highlighted in Figure 1.
Among the novel candidates, we were specially in-
trigued by the reduction in PRKDC shRNA levels in L-
MYC1-overexpressing cells as compared to the isogenic
vector control and L-MYC2-overexpressing cell lines
(Figure 1 and Additional file 1: Table S1). PRKDC en-
codes for the catalytic subunit of the DNA-dependent
serine/threonine-protein kinase (also widely known as
DNA-PKcs). It functions as a molecular sensor for
damaged DNA and engages in DNA non-homologous
end joining (NHEJ) required for double-strand break
(DSB) repair and somatic recombination [29-31]. Previ-
ous research reported that downregulation of PRKDC
by siRNA leads to a decrease of MYC protein level in
Hela cells [32]. Moreover, MYC-induces upregulation
of γH2AX, a protein heavily implicated in DSB [33,34].
We hypothesized that since MYC-driven cancer cells
may be more dependent on DNA damage pathways,
PRKDC is an attractive candidate for a druggable syn-
thetic lethal gene.Figure 1 Large-scale RNAi screen identifies PRKDC as a MYC synthetic
lines stably-expressing empty vector (pCDH), L-MYC1 or L-MYC2, after infectio
expression; intensity of color represents relative counts per million total re
synthetic lethal partners of MYC.PRKDC knockdown in L-MYC overexpressing lung
fibroblasts and cancer cells decreases cell viability
Next, we wanted to reconfirm the functional conse-
quence of PRKDC suppression in the context of L-
MYC overexpression. The gene knockdown efficiency
of five shRNAs against PRKDC was confirmed by quan-
titative RT-PCR and Western blot analysis in WI38
cells (Figure 2A). Two shRNAs (shPRKDC-3 and
shPRKDC-5) demonstrating good reduction of PRKDC
expression levels were chosen for functional experiments.
Titration experiments using PRKDC shRNA-expressing
lentiviruses demonstrated a specific decrease in cell viabil-
ity in L-MYC1-overexpressing WI-38 cells as compared to
the control cells (Figure 2B). Significantly, our results
showed PRKDC dependency in cells expressing active L-
MYC, but not in cells expressing an inactive L-MYC
isoform. Similar and reproducible results were ob-
tained using two independent shRNAs (shPRKDC-3
and shPRKDC-5) (Figure 2B). Moreover, we subjected
WI-38 cells to PRKDC inhibition using a potent and se-
lective PRKDC inhibitor, NU-7441 [35]. With increasing
PRKDC inhibitor concentrations, we noted a marked de-
crease in cell viability for L-MYC1-overexpressing cells
when compared to controls (Figure 2C). All cell lines dis-
played similar growth curves in the absence of the PRKDC
inhibitor (Additional file 2: Figure S1). Our data suggests
that the MYC oncogene confers a dependency on PRKDC
for cell viability and makes cells sensitive to PRKDC
inhibition.lethal gene. Heat map of relative counts of 18 shRNAs for WI-38 cell
n with a pooled kinase shRNA library. Blue = high expression, red = low
ads. Highlighted in green (CDK2 and GSK3B) are previously published
Figure 2 PRKDC gene suppression in MYC-overexpressing human lung fibroblast cells decreases cell viability. A) Gene and protein
knockdown efficiency with independent shRNA clones against PRKDC quantified by RT-PCR and immunoblotting, respectively, in WI-38 cells. Protein
was analyzed via immunoblotting for PRKDC (anti-PRKDC) and GAPDH (anti-GAPDH). B) Stable WI-38 cell lines were exposed to increasing amounts of
lentivirus expressing PRKDC shRNAs and subjected to a cell viability assay after 6 days. C) Stable WI-38 cell lines were treated with varying
concentrations of a PRKDC inhibitor, NU-7441, for 3 days and subjected to a cell viability assay. Data are shown as mean ± SD. Statistical analysis using
one-way ANOVA; ****P ≤0.0001; ***P ≤ 0.001; **P ≤ 0.01.
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proliferation and is dependent on high MYC expression
levels
To further test our findings in cancer cells, we investi-
gated PRKDC suppression in a panel of human small-
cell lung cancer (SCLC) cell lines with differential levels
of MYC family gene amplification and mRNA expres-
sion. It was reported that the L-MYC gene was ampli-
fied in H209 and H1963 cell lines, c-MYC was
amplified in H524 and N-MYC was amplified in the
H526 cell line. None of the MYC family genes were
amplified in H196 and SW1271. By TaqMan RT-PCR,
we confirmed that mRNA expression levels of MYC
family genes (as compared to 293 T cells and this panel
of SCLC lines) are correlated with their gene amplifica-
tion status (Figure 3A). Functionally, inhibition of
PRKDC using NU-7441 preferentially killed cells with
either L-MYC (H209 and H1963), c-MYC (H524) or N-
MYC (H526) overexpression, compared to cell lines
without MYC family gene overexpression (H196 and
SW1271) (Figure 3B).
To confirm inhibition of PRKDC preferentially kills
SCLC tumor cells with MYC overexpression, we used
shRNAs to knockdown PRKDC. Since many SCLC cell
lines grow in suspension and form big clumps, evaluationof PRKDC knockdown effects on cell growth using con-
stitutive shRNAs was difficult. We therefore decided to
use doxycycline-regulated inducible shRNAs for PRKDC
downregulation for these experiments. Briefly, cancer cells
were stably infected with inducible TetOn lentiviruses
where the expression of PRKDC shRNA was under the
control of the doxycycline promoter. In vitro, PRKDC
knockdown was confirmed via PRKDC-specific TaqMan
and Western blot analysis in each SCLC cell line tested in
response to doxycycline treatment (Figure 3D-G). Differ-
ent SCLC cell lines with differential MYC expression
patterns (Figure 3C) were exposed to doxycycline for 7–
13 days in vitro (Figure 3D-G). While inducible knock-
down of PRKDC in SW1271 (cell line with no MYC gene
amplification) had minimal effect on growth inhibition
(Figure 3D), the same treatment of H209 cells (L-MYC
gene amplification) greatly inhibited cell proliferation
(Figure 3E). Similar results of cell proliferation inhibition
were observed in H524 (c-MYC gene amplification) and
H69 (N-MYC gene amplification) cell lines upon PRKDC
knockdown (Figure 3F-G). The data is consistent with our
hypothesis that PRKDC loss-of-function synthetic lethality
is reliant on highMYC expression levels.
In order to further validate PRKDC dependency in
other MYC-driven cancers, we chose to examine c-MYC
Figure 3 Inducible PRKDC knockdown decreases human SCLC cell proliferation and is dependent on high MYC expression levels.
A) MYC family gene expression levels in non-isogenic SCLC cell lines (as compared to MYC family gene expression levels in 293 T cells). B) SCLC
cell lines with different levels of MYC gene expression were treated with varying concentrations of a PRKDC inhibitor, NU-7441, for 3 days and subject
to a cell viability assay. C) MYC gene amplification status in different SCLC cell lines. D-G) SCLC cell lines were subjected to inducible PRKDC
downregulation with three independent shRNA clones and knockdown was confirmed via immunoblotting and RT-PCR after doxycycline
exposure. Protein was analyzed via immunoblotting for PRKDC (anti-PRKDC) and GAPDH (anti-GAPDH). The SCLC cell lines were exposed to
doxycycline for 6–13 days and then subjected to a cell viability assay. Data are shown as mean ± SD. Statistical analysis using one-way ANOVA;
****P ≤0.0001; ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05.
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inhibitors, NU-7441 and KU0060648 [36]. We selected a
panel of human lymphoma cell lines and divided them
into c-MYC high and low groups (BioGPS database).
The IC50 of the two PRKDC inhibitors were measured
in a cell proliferation assay in these cell lines (Additional
file 3: Figure S2A). Cell lines with high c-MYC gene ex-
pression levels were more responsive to NU-7441 ascompared to the low c-MYC expression cohort, displaying
IC50 values of 2.09 ± 0.56 μM and 13.76 ± 5.18 μM, respect-
ively (Additional file 3: Figure S2B). A similar IC50 trend
for KU0060648 was observed in these cells (1.09 ± 0.23 μM
and 9.27 ± 4.71 μM, respectively) (Additional file 3:
Figure S2B). Together, our results suggest that the MYC
oncogenic effect is dependent on PRKDC expression in
multiple human cancers with high MYC expression levels.
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protein abundance in cancer cell lines
Our data suggested synthetic lethality of PRKDC in
MYC-overexpressing cancers. We next wanted to gain
insight into the underlying mechanism. It was reported
that PRKDC can induce phosphorylation of MYC at
various serine residues and modulate its stability [37].
Moreover, it has been observed that knockdown of
PRKDC via RNAi reduces MYC protein stability in Hela
cells [32,38].
We examined c-MYC protein expression levels in
lymphoma cell lines treated with the PRKDC inhibitor,
KU0060648. After a 4 h drug treatment, we noted a sig-
nificant and dose-dependent decrease in c-MYC pro-
tein levels in multiple lymphoma cell lines, correlating
with a concurrent decrease in c-MYC mRNA expres-
sion (Figure 4A and B, respectively). Furthermore, using
our inducible PRKDC shRNA knockdown system in
H82 SCLC cells, we observed a concomitant reduction
in c-MYC protein when cells were exposed to doxycyc-
line (Figure 4C). Interestingly, the proteasome inhibitor,
MG132, did not completely rescue the effect of PRKDC
inhibition on MYC abundance (Figure 4A). Similar re-
sults were observed with another PRKDC inhibitor,
NU-7441, when used in conjunction with MG132
(Additional file 4: Figure S3). Collectively, these data
indicate that PRKDC modulates c-MYC mRNA andFigure 4 MYC mRNA and protein levels are negatively affected by PR
cell lines were treated with increasing concentrations of the PRKDC inhibit
exposure time, c-MYC protein levels were analyzed via immunoblotting wi
monitored with anti-PRKDC and anti-GADPH antibodies, respectively. B) Cells
levels. C) The H82 cell line expressing inducible PRKDC shRNA was exposed to
analyzed by immunoblotting with anti-MYC antibody, anti-PRKDC and an
independent shRNA clones against PRKDC was quantified by RT-PCR as wprotein expression in these cancer cell lines; the effect
on MYC protein abundance is at least in part through
reduction of MYC mRNA.
Overexpression of MYC family proteins induces
double-strand breaks in DNA in a SV40-transformed
human lung cell line
In addition to the modulation of MYC protein and
mRNA abundance by PRKDC, there is further interplay
between the two proteins during DNA damage and re-
pair processes. It was reported that overexpression of c-
MYC induces DNA DSB [33,39]. Our hypothesis is that
in cancer cells, MYC overexpression induces DSBs and
PRKDC plays a pivotal function in repairing this DNA
damage, leading to cancer cell survival. Therefore, we
overexpressed MYC in WI-38 VA13 cells, a SV40-
transformed human lung cell line, and monitored for
phosphorylated histone H2AX (γH2AX). γH2AX is a
commonly used biomarker of DNA damage, which
quickly accumulates in the cell following DSB induction
to elicit amplification of the DNA damage response sig-
naling cascade [40-42]. Our results showed that overex-
pression of MYC induced a substantial increase in
γH2AX in WI-38 VA13 cells (Figure 5), which is consist-
ent with previous reports [33,39]. This was a universal
finding for all MYC family members (c-, L-, and N-
MYC) (Figure 5). As a positive control for DNA damageKDC gene suppression in cancer cell lines. A) Different lymphoma
or, KU0060648, and a proteasome inhibitor, MG132. After a 4 h drug
th an anti-MYC antibody. PRKDC and GADPH protein levels were also
from A were analyzed by RT-PCR for relative c-MYC mRNA expression
doxycycline for 3 days. c-MYC, PRKDC and GADPH protein levels were
ti-GADPH antibodies, respectively. Gene knockdown efficiency with
as relative c-MYC mRNA expression levels in these cell lines.
Figure 5 MYC overexpression induces double-strand breaks in DNA. A) A SV40-transformed human lung cell line, WI-38 VA13, stably-expressing
c-MYC, L-MYC, or N-MYC, were lyzed and immunoblots were analyzed for phosphorylated histone H2AX (anti-γH2AX) and GADPH (anti-GADPH). As a
positive control for DNA damage detection, parental cells were treated with etoposide and analyzed via immunoblotting. Cell lysates were
also analyzed for overexpression of MYC variants. B) The same cells lines as in A were treated with the PRKDC inhibitor, KU0060648, for 8 h,
lyzed and immunoblotted for phosphorylated histone H2AX (anti-γH2AX) and γ-tubulin (anti-γ-tubulin). Signal intensities of immunoblots were
quantified using ImageJ.
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drug which causes DNA damage [43], and observed an
increase in γH2AX expression (Figure 5). Additionally,
inhibition of PRKDC in MYC-overexpressing cells fur-
ther increased γH2AX levels. Our results suggest that,
mechanistically, the synthetic lethality observed be-
tween PRKDC suppression and MYC overexpression
may in part be due to the reliance of MYC-expressing
cancer cells on PRKDC-mediated DNA damage repair.
Discussion
The MYC family encodes transcription factors which play a
critical role in diverse biological and pathophysiological pro-
cesses. Amplification of the MYC oncogene commonly oc-
curs in various types of human cancers. Not only has MYC
been established as a ‘driver’ oncogene capable of initiating
tumor formation, it has also been demonstrated that tumors
become addicted to MYC and require MYC for tumor
maintenance [44]. Multiple in vivo MYC-overexpression
cancer murine models further support MYC as a thera-
peutic target [44]. Thus, due to MYC’s critical role in human
cancer, mounting research efforts have been made to iden-
tify potential therapies for MYC-driven cancer. However,
pharmacologic inhibition of MYC function has proven chal-
lenging, partially due to the absence of an apparent drug-
gable domain in MYC transcription factors. Modulators that
regulate MYC gene expression or protein abundance would
be alternative therapeutic targets. Brd4, an epigenetic regula-
tor of MYC, has been identified as a promising drug target
for MYC-driven cancer [45]. Downregulation of MYC
transcription by BET inhibitor, JQ1 compound, resulted insignificant anti-tumor activity in mouse models [46,47].
This is consistent with the notion that MYC overexpres-
sion in cells leads to oncogene addiction, a phenomenon
where a tumor becomes reliant on a single dominant
oncogene for growth and survival. Thus, MYC reduction
through pharmacological intervention provides potential
strategies to target MYC-driven cancer.
Studies to target MYC via synthetic lethality have re-
ported multiple MYC synthetic lethal partners, such as
ARK5, ATR, AURKB, CDK1/2, CHK1, CSNK1ε, DR5,
GSK3B, and SAE1/2 [6,27,28,48-54]. However, all these
candidates remain to be validated in the clinic.
Pooled shRNA technology has made substantial pro-
gress in the last several years, with more sophisticated
shRNA pools, increased deep sequencing capacity and
reduced cost. Herein, we report identification of a syn-
thetic lethality link between PRKDC and MYC through
pooled shRNA screening and demonstrate inhibition of
PRKDC preferentially kills MYC-overexpressing tumor
cells.
PRKDC is a vital component of NHEJ DNA repair.
Germ-line loss-of-function PRKDC mutations lead to
disruption of T or B cell development and a severely
compromised immunodeficiency phenotype in humans
and mice [55,56]. Nevertheless, PRKDC is not essential
in model organisms, demonstrated in both genetically
engineered and spontaneous animal models [55,57-60],
which may afford a potential safe therapeutic window
for future drug development. To this end, in pre-
clinical animal models, PRKDC inhibitors such as NU-
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Figure 6 Proposed model for synthetic lethality between MYC and PRKDC. A) In MYC-driven cancer cells, the overexpression of MYC leads
to DNA damage and creates a dependence on DNA repair machinery for cancer cell survival. Double strand breaks (DSBs) induce non-homologous
end joining (NHEJ) DNA repair mechanisms to correct for DNA insult. PRKDC is a major player during NHEJ repair, and along with other key
components, will restore the impaired DNA allowing for cancer cell viability. In these same cells, exposure to anti-PRKDC drug treatments
would ultimately lead to PRKDC inhibition, compromised NHEJ repair and cell death. B) PRKDC has also been implicated in MYC gene regulation. i) In
a normal setting, MYC protein is phosphorylated through RAF- and AKT-mediated signaling cascades, resulting in its FBW7-mediated ubiquitination,
and subsequent proteasomal degradation. ii) In cancer cells, at the gene level, the inhibition of PRKDC protein decreases MYC expression, potentially
through a direct effect or epigenetic mechanism(s). iii) Additionally in cancer cells, PRKDC can phosphorylate AKT, which results in the inhibition of
GSK3β and subsequent MYC degradation. Therefore, interference with PRKDC function(s) decreases the stability of MYC protein. This form of genotypic
cytotoxicity represents synthetic lethality that selectively targets cancer cells while leaving normal cells unscathed, and offers a potential for
wider therapeutic windows for cancer therapies.
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the dual PI3K/mTOR inhibitor, BEZ235, has displayed
robust anti-PRKDC activities and inhibition of tumor
growth in pre-clinical mouse models; CC-115 also has
a similar mTOR/PRKDC dual inhibition activity [62-65].
Currently, clinical trials are underway with BEZ235 and
CC-115 to determine its efficacy and safety in human
patients [66]. It will be of great interest to dissect if its
PRDKC activity could contribute to its tumor efficacy.
At the cellular level, MYC-induced γH2AX protein
upregulation, a hallmark for DSB and replicative stress
where PRKDC has an essential function, suggesting
that MYC-driven cancer cells may be more dependent
on DNA damage response components. MYC expres-
sion induces DSB formation, which if left unchecked,
results in DNA damage and cell death [33,34] (Figure 6).
We hypothesize that MYC-overexpressing cancer cells
may become more reliant on the DNA damage repair
machinery of PRKDC for survival. Suppression of this
DNA repair pathway would then lead to cancer cell
death (Figure 6).
Consistent with our data, other components in the
DNA damage response (DDR) pathway, such as ATR,
are also implicated in MYC synthetic lethality [50]. In
genetically engineered mouse models, reduction of
ATR prevented MYC-driven lymphomas or pancreatic
tumors [50]. In contrast, genetic ablation of ATR had
no effect in Kras G12V-driven pancreatic tumor models
[50]. Mechanistically, DSB initiates a signaling cascade
through ATR and ATM-mediated phosphorylation events,
which signals checkpoint proteins CHK1 and CHK2 to
induce cell cycle arrest. It is a critical phase required
to signal for DSB repair. Thus, disruption of ATR in
human or model organisms hinders DNA repair. We
hypothesize that a similar disruption of PRKDC and its
vital role in controlling genomic instability would have
selective cytotoxic effects in cells with replicative stress
induced by MYC. Future studies with in vivo models
where this PRKDC-MYC connection is perturbed will
be essential in order to fully appreciate its clinical im-
portance and relevance.Aside from its involvement in NHEJ DNA repair,
PRKDC has also been implicated in gene regulation
and protein abundance. It was reported that RNAi-
mediated knockdown of PRKDC decreased the abun-
dance of MYC protein in Hela cells [32]. Mechanistically,
phosphorylation of MYC protein on residues Thr58 by
GSK3β is essential for its FBW7-mediated proteasomal
degradation. Interestingly, it was reported that PRKDC
can phosphorylate AKT, which results in the inhibition
of GSK3β and subsequent MYC degradation. [32].
Thus, a possible scenario is cancer cells that are
‘addicted’ to MYC become highly sensitive to hindrance
of PRKDC function, leading to subsequent interference
of MYC transcription and protein translation and can-
cer cell death (Figure 6).
A number of studies have suggested that PRKDC acts
as a modulator of gene transcription. PRKDC phos-
phorylates a variety of transcription factors including
FOS, JUN, SP1, OCT-1, TFIID, E2F, the estrogen recep-
tor, and the large subunit of RNA polymerase II [67,68].
PRKDC is also thought to be required for transcrip-
tional regulation mediated by transcription factors,
such as lymphocyte enhancer factor 1 (LEF1) [69], heat
shock transcription factor (HSF) [70], p53 and the product
of the predominant ETS gene fusion, TMPRSS2:ERG,
in prostate cancer [71]. Future studies should be di-
rected towards investigating whether targeting PRKDC
in these settings may have beneficial outcomes.
Conclusions
Targeting cancer with synthetic lethal partners offers a
unique advantage to leave normal tissues unscathed
and destroying only the cancer cells. Our study demon-
strates that inhibition of PRKDC may offer a thera-
peutic strategy in MYC-driven cancers.
Additional files
Additional file 1: Table S1. Summary of deep sequencing results for
the screen using WI-38 cell lines stably-expressing empty vector (pCDH),
L-MYC1 or L-MYC2, after infection with a pooled kinase shRNA library.
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in the sample; ie (raw reads)/(total reads in the sample) × 106). Minimal
requirement for the reads in pCDH-L-MYC1 sample on day 1 is 500. The
table is sorted on RPM in pCDH-L-MYC1 sample on day 14. The top nine
genes from this table with less than three-fold reduction in control Day1
versus Day14 samples were selected for follow-up.
Additional file 2: Figure S1. Stable WI-38 cell lines were subject to a
cell viability assay at days 1, 3, 5 and 7 and growth curves were analyzed.
Data are shown as mean ± SD. Statistical analysis using one-way ANOVA;
****P ≤0.0001; ***P ≤ 0.001; **P ≤ 0.01.
Additional file 3: Figure S2. Human lymphoma cell lines were divided
into two groups, high MYC and low MYC gene expression (BioGPS database
values), and treated with PRKDC inhibitors, NU-7441 and KU0060648, for 3
days. Cells were subject to cell viability assays and IC50 of the two
PRKDC inhibitors were measured in these cell lines. High MYC and low
MYC expression cell lines treated with NU-7441 displayed IC50 values of
2.09 + 0.56 μM and 13.76 + 5.18 μM, respectively. The two groups
followed a similar trend in terms of IC50 when cells were treated with
KU0060648 (1.09 + 0.23 μM and 9.27 + 4.71 μM, respectively). Data are
shown as mean ± SEM. Statistical analysis using unpaired t test
(Mann-Whitney test); **P ≤ 0.01.
Additional file 4: Figure S3. Different lymphoma cell lines were
treated with increasing concentrations of the PRKDC inhibitor, NU-7441,
and a proteasome inhibitor, MG132. After a 4 h drug exposure time,
c-MYC protein levels were analyzed via immunoblotting with an anti-MYC
antibody. PRKDC and GADPH protein levels were also monitored with
anti-PRKDC and anti-GADPH antibodies, respectively.
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